The Foundation for Government Accountability (FGA) has expressed approval of the Trump administration’s renewed focus on health care price transparency. The administration recently filed a Request for Information (RFI) to gather public input on implementing rules that require insurance companies to disclose actual prescription drug prices. This initiative aims to provide patients with clear and upfront pricing information, aligning with FGA’s longstanding advocacy efforts.
In 2023, FGA sued the Biden administration over delays in enforcing these transparency rules. The lawsuit resulted in the restoration of enforcement measures. “Patients deserve to know what their health care costs are before they receive a surprise bill in the mail,” stated Tarren Bragdon, President and CEO of FGA. He praised President Trump’s actions as a significant move towards fairness and accountability in health care.
Bragdon further emphasized FGA’s commitment to holding the Biden administration accountable for its previous stance on patient transparency. “We took the administration to court—and we won—because Americans deserve honesty and transparency in their health care,” he said. He acknowledged President Trump as a partner in ensuring families have access to transparent medical cost information.
Despite legal victories regarding hospital and prescription drug pricing disclosure, FGA noted ongoing challenges with record withholding and enforcement delays under the Biden administration. Recently, President Trump signed an executive order reinstating his first-term rule aimed at empowering patients through price transparency.
The Foundation for Government Accountability is a non-profit organization focused on promoting public policy solutions that create opportunities for Americans.
